Papillomaviruses

Disease Agent:
- Human papillomavirus (HPV)

Disease Agent Characteristics:
- Family: *Papillomaviridae*; Genus: *Alpha-Papillomavirus*
- Virion morphology and size: Nonenveloped, icosahedral nucleocapsid symmetry, spherical particles, 52-55 nm in diameter
- Nucleic acid: Circular, double-stranded DNA, 7.9 kb in length with unidirectional transcription
- Physicochemical properties: Sparse information; presumably susceptible to 0.3% povidone-iodine, to polysulfated and polysulfanated compounds, and to dilute solutions of sodium dodecyl sulfate; ether-resistant, acid-stable, and heat-stable

Disease Name:
- Nongenital skin warts
- Epidermodysplasia verruciformis
- Anogenital warts (condylomas)
- Nonmelanoma skin cancer
- Cervical cancer
- Anogenital cancer, penile cancer
- Papillomas of respiratory tract, larynx, mouth, or conjunctiva that includes oral and laryngeal cancers

Priority Level:
- Scientific/Epidemiologic evidence regarding blood safety: Theoretical
- Public perception and/or regulatory concern regarding blood safety: Absent
- Public concern regarding disease agent: Low/Moderate

Background:
- Stable in population
- Narrow host range restricted to sites with stratified squamous epithelia that are cornified (skin) or non-cornified (genital and nongenital mucosa)
- High risk types found most frequently in association with cervical cancer
- New disease associations have been recognized over time.

Common Human Exposure Routes:
- Infection of basal keratinocytes primarily through wounds or skin abrasions
- Contact with infected tissue or contaminated objects
- Autoinoculation from site to site
- Sexual intercourse
- Delivery through infected birth canal

Likelihood of Secondary Transmission:
- High by direct contact, especially in older children and young adults
- High by sexual contact

At-Risk Populations:
- Older children and young adults (nongenital skin warts)
- Persons who are sexually active with multiple partners
- Adult patients with Fanconi anemia
- HPV-infected persons exposed to sun or UV light
- Increased susceptibility in immune suppressed patients

Vector and Reservoir Involved:
- None

Blood Phase:
- One study found HPV DNA in PBMCs, serum, and plasma of patients with cervical and neck cancers and in 3 of 19 (15%) PBMCs from healthy blood donors.

Survival/Persistence in Blood Products:
- Unknown

Transmission by Blood Transfusion:
- In a recent study of 57 HIV-infected children, seven of eight who were HPV DNA positive had a history of blood and/or plasma derivative transfusion as the cause of their HIV infection.
- Bovine papillomavirus type 2 has been transmitted through blood via intramuscular inoculations.

Cases/Frequency in Population:
- Over 100 HPV types have been identified, 13 of which have been strongly or moderately associated with cervical cancer.
- 2-3% of women undergoing routine Pap smear have abnormal cytology, the majority of which is associated with HPV.
- The peak prevalence is seen in women 15-25 years of age, which may be 25-40%, and then declines with increasing age.

Incubation Period:
- Limited information because exposures are generally multiple and onset is insidious

Likelihood of Clinical Disease:
- Varies with the particular strain
Primary Disease Symptoms:

- The typical skin lesion, the wart, is easily recognized, particularly when in its most common location, the hands or feet (plantar warts). Most spontaneously regress.
- Anogenital warts are also easy to recognize but may be internal and only observed following an appropriate examination. These can be recurrent, sometimes painful, and difficult to treat but may spontaneously remit.
- Cervical intraepithelial neoplasia and cervical cancer are often asymptomatic and only detected on routine examination, primarily after cervical cytology has been assessed. Symptoms, such as bleeding and pain, appear as the cancer expands and disseminates.
- Other symptoms depend on location of the papilloma and can include vocal disturbances from laryngeal papillomatosis, pulmonary dysfunction from respiratory tract involvement, and local discomfort from oral lesions.

Severity of Clinical Disease:

- Generally benign, except that it can lead to cervical and anal cancers (most common cause of these malignancies), and benign papillomatosis can be debilitating because of location (e.g., laryngeal disease).

Mortality:

- Highly dependent on genotype and whether cancer ensues. Mortality is low, even in cancer patients if early methods of detection are employed.

Chronic Carriage:

- Chronic infection is typical although there is late spontaneous clearance. However, chronic viremia is unlikely. HPV may be carried in WBCs that intermittently seed the blood stream.

Treatment Available/Efficacious:

- There are a variety of treatments for disease caused by HPV, ranging from simple intralesional or parenteral interferon or destructive therapy for genital warts, to surgery, laser excision repair, cryotherapy, or chemotherapy for high-grade dysplasia for cervical infection or cervical cancer. Successful therapy is associated with the disappearance of HPV DNA.
- Therapeutic vaccines have had only limited success.
- Not indicated because transfusion transmission has not been demonstrated.
- No sensitive or specific question is feasible.

Laboratory Test(s) Available:

- No FDA-licensed blood donor screening test exists.
- Tissue diagnosis is usually by nucleic acid hybridization or extraction of DNA followed by NAT. Southern blots of extracted DNA are the gold standard and allow for subtyping.
- Electron microscopy for viral particles or immunologic detection of viral capsid antigens has low sensitivity. Detection in PBMCs is generally performed by PCR or nested PCR.

Currently Recommended Donor Deferral Period:

- No FDA Guidance or AABB Standard exists.
- There is no indication for deferral of individuals with known HPV infection unless presenting with a deferrable malignancy.

Impact on Blood Availability:

- Agent-specific screening question(s): Not applicable
- Laboratory test(s) available: Not applicable

Impact on Blood Safety:

- Agent-specific screening question(s): Not applicable
- Laboratory test(s) available: Not applicable

Leukoreduction Efficacy:

- Unknown, but if virus is carried in peripheral blood, it is probably within PBMCs, and thus leukoreduction would be expected to have some impact.

Pathogen Reduction Efficacy for Plasma Derivatives:

- This is a nonenveloped virus and thus would not be affected by solvent-detergent treatment.
- No data from model viruses

Other Preventive Measures:

- Pathogen reduction strategies based on inactivation of DNA should be effective.
- A quadrivalent human papilloma vaccine (Gardasil, MSD) is available against HPV types 6, 11, 16, and 18, which cause 70% of cervical cancer cases and 90% of genital warts cases.

Suggested Reading: